BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17050951)

  • 1. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.
    Nakane M; Kolasa T; Chang R; Miller LN; Moreland RB; Brioni JD
    J Pharmacol Sci; 2006 Oct; 102(2):231-8. PubMed ID: 17050951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
    Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
    Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A-350619: a novel activator of soluble guanylyl cyclase.
    Miller LN; Nakane M; Hsieh GC; Chang R; Kolasa T; Moreland RB; Brioni JD
    Life Sci; 2003 Jan; 72(9):1015-25. PubMed ID: 12495780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
    Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
    Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
    Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
    J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
    Nakane M; Hsieh G; Miller LN; Chang R; Terranova MA; Moreland RB; Kolasa T; Brioni JD
    Int J Impot Res; 2002 Apr; 14(2):121-7. PubMed ID: 11979328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
    Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
    Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
    BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
    Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
    Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
    Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
    Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
    Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
    PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.
    Nimmegeers S; Sips P; Buys E; Brouckaert P; Van de Voorde J
    Cardiovasc Res; 2007 Oct; 76(1):149-59. PubMed ID: 17610859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra.
    Toque HA; Antunes E; Teixeira CE; De Nucci G
    Urology; 2008 Sep; 72(3):711-5. PubMed ID: 18359064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.
    Mujoo K; Sharin VG; Martin E; Choi BK; Sloan C; Nikonoff LE; Kots AY; Murad F
    Nitric Oxide; 2010 Jan; 22(1):43-50. PubMed ID: 19948239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide.
    Teixeira CE; Priviero FB; Claudino MA; Baracat JS; De Nucci G; Webb RC; Antunes E
    Eur J Pharmacol; 2006 Jan; 530(1-2):157-65. PubMed ID: 16371226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
    Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
    Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of soluble guanylate cyclase alpha(1) and alpha(2), and SK(Ca) channels in NANC relaxation of mouse distal colon.
    Dhaese I; Vanneste G; Sips P; Buys E; Brouckaert P; Lefebvre RA
    Eur J Pharmacol; 2008 Jul; 589(1-3):251-9. PubMed ID: 18572161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
    Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
    Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.